Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $75.3 million.

  • Prestige Consumer Healthcare's Free Cash Flow rose 1847.15% to $75.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $267.2 million, marking a year-over-year increase of 743.95%. This contributed to the annual value of $243.3 million for FY2025, which is 163.55% up from last year.
  • Latest data reveals that Prestige Consumer Healthcare reported Free Cash Flow of $75.3 million as of Q4 2025, which was up 1847.15% from $55.4 million recorded in Q3 2025.
  • In the past 5 years, Prestige Consumer Healthcare's Free Cash Flow registered a high of $78.2 million during Q2 2025, and its lowest value of $46.6 million during Q2 2023.
  • Over the past 5 years, Prestige Consumer Healthcare's median Free Cash Flow value was $59.0 million (recorded in 2021), while the average stood at $60.9 million.
  • In the last 5 years, Prestige Consumer Healthcare's Free Cash Flow soared by 4728.61% in 2021 and then tumbled by 1851.4% in 2023.
  • Prestige Consumer Healthcare's Free Cash Flow (Quarter) stood at $64.1 million in 2021, then decreased by 17.06% to $53.1 million in 2022, then soared by 30.74% to $69.5 million in 2023, then dropped by 8.57% to $63.5 million in 2024, then increased by 18.47% to $75.3 million in 2025.
  • Its last three reported values are $75.3 million in Q4 2025, $55.4 million for Q3 2025, and $78.2 million during Q2 2025.